Universe Pharmaceuticals INC UPC PHARMA
Company Overview
Universe Pharmaceuticals INC, through its subsidiaries, engages in the manufacturing, marketing, distribution, and sales of traditional Chinese medicine derivative products in China. The company offers products for the treatment and relief of common chronic health conditions in the elderly for physical wellness and longevity; and cold and flu medications. It also provides guben yanling, shenrong weisheng, and quanlu pill; yangxue danggui and qiangli pipa syrup; wuzi yanzong oral, fengtong medicinal, shenrong medicinal, qishe medicinal, fengshitong medicinal, and shiquan dabu medicinal liquor; paracetamol granule for children; and isatis root granule. In addition, the company distributes and sells third-party products, including biomedical drugs, medical instruments, traditional Chinese medicine pieces, and dietary supplements. It primarily serves pharmaceutical companies, hospitals, clinics, and drugstore chains. The company was founded in 1998 and is headquartered in Ji'An, China. Universe Pharmaceuticals INC is a subsidiary of Sununion Holding Group Limited.
Why Investors Should Care
Net profit has compounded at 17.9% per year over the last five years.
Carries low leverage with a debt-to-equity ratio of 0.17.
Recent Developments
- Sep 2025 Revenue of $17.86M (-22.4% YoY); net profit $-3.67M.
- Trailing 12 Months Year-on-year growth — revenue -1.3%.
- 5-Year Trend Long-term compounding — revenue CAGR -23.7%, profit CAGR 17.9%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -23.66% |
| 1 Year: | -1.30% |
Compounded Profit Growth
| 5 Years: | 17.86% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | -4.55% |
| 6 Months: | +58.49% |
| 3 Months: | +15.93% |
| 1 Month: | -24.46% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMAAbove
- RSI (14)42.88 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Profit CAGR of 17.9% over 5 years.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Revenue declined at -23.7% CAGR over 5 years.
- Trading 65.5% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | UPC Universe Pharmaceuticals INC PHARMA | 4.20 | -3.04 | $21.03M | 0.00% | -5.19% | -3.50% | -23.66% | 17.86% |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Profit & Loss (Annual)
Figures in USD.
| Metric | Sep 2021 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|---|
| Revenue | - | 40.14M | 32.31M | 23.02M | 17.86M |
| Cost of Revenue | - | 18.25M | 21.99M | 16.95M | 11.56M |
| Gross Profit | - | 21.89M | 10.32M | 6.07M | 6.30M |
| Operating Expenses | - | 28.91M | 14.28M | 14.09M | 9.22M |
| Operating Income | - | -7.02M | -3.97M | -8.02M | -2.92M |
| EBITDA | - | -6.40M | -3.66M | -7.36M | -2.92M |
| Interest Expense | - | 162.40K | 156.79K | 278.17K | 232.04K |
| Pretax Income | - | -7.09M | -4.33M | -8.12M | -3.67M |
| Tax Provision | - | 815.32K | 2.25M | 606.70K | 0 |
| Net Income | - | -7.91M | -6.58M | -8.73M | -3.67M |
| Diluted EPS | - | -1,335.29 | -1,089.21 | -626.96 | -8.06 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Sep 2021 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 59.54M | 41.72M | 67.95M | 69.30M |
| Current Assets | - | 41.51M | 25.27M | 51.64M | 53.60M |
| Cash & Equivalents | - | 5.71M | 5.29M | 29.50M | 33.59M |
| Inventory | - | 2.21M | 3.34M | 1.74M | 2.19M |
| Receivables | - | 15.18M | 11.01M | 12.91M | 13.01M |
| Total Liabilities | - | 13.10M | 13.75M | 22.45M | 13.17M |
| Current Liabilities | - | 13.10M | 13.75M | 20.31M | 13.17M |
| Long Term Debt | - | - | - | 2.14M | - |
| Total Debt | - | 3.94M | 5.48M | 7.99M | 9.26M |
| Total Equity | - | 46.44M | 27.97M | 45.50M | 56.13M |
| Shares Outstanding | - | 6.04K | 6.08K | 39.41K | 563.34K |
Cash Flows (Annual)
Figures in USD.
| Metric | Sep 2021 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -1.30M | 1.12M | -9.51M | -5.05M |
| Investing Cash Flow | - | -3.91M | -44.17K | -361.29K | -341.81K |
| Financing Cash Flow | - | 3.32M | -1.39M | 33.95M | 9.73M |
| Capital Expenditure | - | -93.70K | -44.17K | -363.09K | -347.19K |
| Free Cash Flow | - | -1.40M | 1.07M | -9.87M | -5.40M |
| Net Change in Cash | - | -1.89M | -318.04K | 24.09M | 4.33M |
Ratios (Annual)
Figures in %.
| Metric | Sep 2021 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | 54.5% | 31.9% | 26.4% | 35.3% |
| Operating Margin % | - | -17.5% | -12.3% | -34.8% | -16.3% |
| Net Margin % | - | -19.7% | -20.4% | -37.9% | -20.6% |
| ROE % | - | -17.0% | -23.5% | -19.2% | -6.5% |
| ROCE % | - | -15.1% | -14.2% | -16.8% | -5.2% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | HRT Financial LP | 3.00% | 16.90K | $82.14K |
| 2 | UBS Group AG | 2.55% | 14.37K | $69.82K |
| 3 | Osaic Holdings Inc. | 1.10% | 6.17K | $30.00K |
| 4 | Caitong International Asset Management Co., Ltd | - | 12 | $58 |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for UPC
GME Stock Jumps After-Hours — GameStop Hikes FY26 EBITDA Outlook To $600M, Nearly Double Of FY25 - Stocktwits
<a href="https://news.google.com/rss/articles/CBMi8gFBVV95cUxOYk8zQjI1T1E0em9Ec0ozRmFzcWNNeEd0cWNmTXlKTzU3YlJheWZvRGFpeFA0a1lhS2xQOXhJemVsb2stS1g4ek4xb3hsUG5sRjhkbTJYdnh4Z2lLTk8wVmdsd2lzVDd1RGIzTmNlbkloVTlPZ0twVkFCMHlxeFJVTldVRE4yZklDOVgzU3…
Universe Pharmaceuticals Shares Jump 38.64% After Hours - Universe Pharmaceuticals (NASDAQ:UPC) - Benzinga
<a href="https://news.google.com/rss/articles/CBMiwwFBVV95cUxPcHg0dnZxRmJUTHNFcFhwTkc3V2hEQ3VHa2luZ3ZHbUhQTENRLTItNUJObHpQNFhoVGtLclM1cjhmWjMwMnpLRVU4N3dXYktkNXpic2Frak1wSXJwNkc4Vmo5WXFUaXkzNXhNS2RFdjNKYWpzbDRDN05EaS1uRm96UmFfSm9FMHp1WmYzVm…
Universe Pharmaceuticals (NASDAQ: UPC) acquires Best Praise with 4,376,552 shares - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxQUzRZT0NKNjRhX1VyRzducUJNWjAweXo1NEVwMVo4ekdPdGRzWHVOeVBRaXAxRFJjUlVEMVU1aWFoQ3R6clVkSzRaU2huODN3NWM1UmJaTkNFbF8tNFVoLXNMLVA4ZGlRUG8wVHo3dGxCcUJPSmVpN0FiRnRIQm8tekU4c1p1dE9rX2pIal…
UPC Stock Slides As Momentum Fades From Summer Spike - StocksToTrade
<a href="https://news.google.com/rss/articles/CBMihwFBVV95cUxPemdiblFoZGMwR3hVSExvTE4ycFFuM0dHc1hjRkd4UktPLTlhT0lNcG1pSEdSLXBxRzc1OXVubHNab2tzUWhGTTdzQ29HX3M4YkFYUGh2QjJLd1V1RVpDVDJCTTNaUTZfMHRDc3p6LXc4YUZIbmE0czV0S0RVR3lQQmFldTlxZjg?oc=5" …
UPC Stock Slides As Traders Watch Key Support - timothysykes.com
<a href="https://news.google.com/rss/articles/CBMihgFBVV95cUxOM0lEWE9zVF83dWxEOXFNSi1PQWhuTVFURk40cVJ5VFRsaDQ0TGstdHN5bmxTcWxoaVNHSHhRMUJTV2cyTkNXbTFfMXlnZThHSFlCLWgyaVZyZWp6MlIta2tJMjY0eTlCcFVhX0UzVzE3aGprX1VaaDhJWlpQdmdwZzI3VFIzZw?oc=5" t…
Universe Pharmaceuticals Inc (NASDAQ: UPC) Share Price, UPC Stock News, UPC Share Price & Updates - kalkine.com.au
<a href="https://news.google.com/rss/articles/CBMiVEFVX3lxTE96d1c5cFRqNmZqN2kxSDFHN2hJelY2akU0cWIwajlpTUg2ZWpBTFBwc0F1Q2wyN2dqRnpXZnVGSUNJWUJJVDFtNjlzSkNrc3MxbmZ3Zw?oc=5" target="_blank">Universe Pharmaceuticals Inc (NASDAQ: UPC) Share Pric…
UPC — Frequently Asked Questions
What is the current share price of Universe Pharmaceuticals INC (UPC)?
As of 2026-09-19 21:16 PDT, Universe Pharmaceuticals INC (UPC) trades at $4.20 on NasdaqCM. Its 52-week range is $2.25 to $12.18.
What is the market capitalisation of UPC?
Universe Pharmaceuticals INC (UPC) has a market capitalisation of $21.03M on NasdaqCM.
What is the P/E ratio of UPC?
UPC trades at a trailing price-to-earnings (P/E) ratio of -3.04. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 0.05.
What is the return on equity (ROE) of UPC?
UPC has a return on equity (ROE) of -3.50%. Its return on capital employed (ROCE) is -5.19%.
Is UPC a good stock to buy?
This page provides a data-driven analysis of Universe Pharmaceuticals INC (UPC), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.